Nektar Therapeutics (NKTR) Share-based Compensation (2010 - 2026)

Nektar Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 13.93% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $12.1 million (down 37.95% YoY), while the FY2025 annual figure was $12.6 million, down 41.47% from the prior year.
• Share-based Compensation was $3.4 million for Q1 2026 at Nektar Therapeutics, up from $2.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $21.0 million in Q1 2022 to a low of $2.2 million in Q4 2025.
• Historically, Share-based Compensation has averaged $7.5 million across 5 years, with a median of $6.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation dropped 12.29% in 2022, then slumped 54.34% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $12.7 million in 2022, then tumbled by 43.05% to $7.3 million in 2023, then slumped by 33.79% to $4.8 million in 2024, then plunged by 54.34% to $2.2 million in 2025, then soared by 52.99% to $3.4 million in 2026.
• The last three Share-based Compensation figures came in at $3.4 million (Q1 2026), $2.2 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.